ES2167427T3 - Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca. - Google Patents

Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca.

Info

Publication number
ES2167427T3
ES2167427T3 ES95914882T ES95914882T ES2167427T3 ES 2167427 T3 ES2167427 T3 ES 2167427T3 ES 95914882 T ES95914882 T ES 95914882T ES 95914882 T ES95914882 T ES 95914882T ES 2167427 T3 ES2167427 T3 ES 2167427T3
Authority
ES
Spain
Prior art keywords
growth
mammal
combination
insulin
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914882T
Other languages
English (en)
Inventor
Ross G Clark
Hongkui Jin
Nicholas F Paoni
Renhui Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/284,859 external-priority patent/US5661122A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2167427T3 publication Critical patent/ES2167427T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

SE MUESTRAN METODOS PARA MEJORAR LA CONTRACTIBILIDAD MIOCARDICA Y EL RENDIMIENTO CARDIACO EN UN MAMIFERO CON FALLO CARDIACO CONGESTIVO. EN UN PRIMER METODO UN MAMIFERO CON FALLO CARDIACO CONGESTIVO SE TRATA CON LA ADMIMISTACION DE UNA CANTIDAD EFECTIVA DE LA COMBINACION DE HORMONA DE CRECIMIENTO (GH) Y EL FACTOR DE CRECIMIENTO INSULINOIDE (IGF-I). UN SEGUNDO METODO CONSISTE EN LA ADMINISTRACION AL MAMIFERO DE UNA CANTIDAD EFECTIVA DE UNA COMBINACION DE GH E IGF-I EN PRESENCIA DE UN INHIBIDOR ACE. ESTE METODO DA LUGAR A UNA MEJORA DE LA CONTRACTILIDAD MIOCARDICA Y DEL RENDIMIENTO CARDIACO SOBRE EL NIVEL CONSEGUIDO CON LA INHIBICION ACE SOLA. PREFERIBLEMENTE, EL MAMIFERO ES UN SER HUMANO.
ES95914882T 1994-04-15 1995-03-30 Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca. Expired - Lifetime ES2167427T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22792394A 1994-04-15 1994-04-15
US08/284,859 US5661122A (en) 1994-04-15 1994-08-02 Treatment of congestive heart failure
US08/333,909 US5610134A (en) 1994-04-15 1994-11-03 Treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
ES2167427T3 true ES2167427T3 (es) 2002-05-16

Family

ID=27397790

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914882T Expired - Lifetime ES2167427T3 (es) 1994-04-15 1995-03-30 Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca.

Country Status (13)

Country Link
US (1) US5610134A (es)
EP (1) EP0755265B1 (es)
JP (1) JP3473623B2 (es)
AT (1) ATE208209T1 (es)
AU (1) AU691273B2 (es)
CA (1) CA2185998C (es)
DE (1) DE69523747T2 (es)
DK (1) DK0755265T3 (es)
ES (1) ES2167427T3 (es)
HK (1) HK1003418A1 (es)
LV (1) LV12966B (es)
PT (1) PT755265E (es)
WO (1) WO1995028174A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3182307B2 (ja) * 1994-12-27 2001-07-03 株式会社荏原製作所 全周流型ポンプ
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) * 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6015384A (en) * 1998-08-31 2000-01-18 Acuson Corporation Ultrasonic system and method for tissue viability imaging
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
CZ200260A3 (cs) * 1999-07-12 2002-04-17 Grandis Biotech Gmbh Formulace růstového hormonu
JP2003527844A (ja) * 2000-02-11 2003-09-24 ジェネンテック・インコーポレーテッド 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
FR2805051B1 (fr) * 2000-02-14 2002-12-06 Geophysique Cie Gle Methode de surveillance sismique d'une zone souterraine par utilisation simultanee de plusieurs sources vibrosismiques
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6607517B1 (en) 2001-08-24 2003-08-19 Radiant Medical, Inc. Method of inotropic treatment of heart disease using hypothermia
WO2004060310A2 (en) 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
WO2006076342A2 (en) * 2005-01-11 2006-07-20 Heart Failure Technologies, Inc. Method and system for treating heart failure
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
EP2227238A2 (en) 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
EP2225362A1 (en) 2007-11-30 2010-09-08 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ATE133073T1 (de) * 1990-10-25 1996-02-15 Genentech Inc Verwendung gegen reaktive sauerstoffverbindungen schützender wirkstoffe
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
AU691273B2 (en) 1998-05-14
CA2185998A1 (en) 1995-10-26
AU2195695A (en) 1995-11-10
JPH09512008A (ja) 1997-12-02
WO1995028174A1 (en) 1995-10-26
LV12966B (en) 2003-05-20
DK0755265T3 (da) 2002-03-04
EP0755265B1 (en) 2001-11-07
US5610134A (en) 1997-03-11
CA2185998C (en) 2011-02-22
DE69523747T2 (de) 2002-08-01
DE69523747D1 (de) 2001-12-13
ATE208209T1 (de) 2001-11-15
EP0755265A1 (en) 1997-01-29
HK1003418A1 (en) 1998-10-30
PT755265E (pt) 2002-04-29
JP3473623B2 (ja) 2003-12-08

Similar Documents

Publication Publication Date Title
ES2167427T3 (es) Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca.
ATE470448T1 (de) Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
ATE390932T1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
PL338705A1 (en) Application of gaba analogues in preventing and treating gastrointestinal diseases
ATE433324T1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
BR9709068A (pt) Processo de tratamento.
PT1267897E (pt) Tratamento da insufuciencia cardiaca congestiva com sangue autologo previamente tratado
AU2003291004A1 (en) Stress reduction pacing mode for arrhythmia prevention
RU2005102593A (ru) Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани
ATE223228T1 (de) Verwendung von latenz assoziierten peptiden in der herstellung eines medikaments zur verbesserung der wundheilung.
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
PL329077A1 (en) Method of treating cardiac insufficiency by means of endotelin antagonists
MX9604803A (es) Combinacion de hormona del crecimiento y factor de crecimiento similar a insulina para el tratamiento del fallo cardiaco congestivo.
DE69110615D1 (de) Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung.
DE69305091T2 (de) Methode zur behandlung oder verhütung von fettleibigkeit
ATE239497T1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
Numata et al. Possible involvement of hypothyroidism as a cause of lithium‐induced sinus node dysfunction
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
GEP19980848B (en) Method for Treatment of Chronic Inflammatory Processes and Comlications Developed on its Bases
RU94018734A (ru) Способ сохранения парадонтозных и плоходержащихся (шатающихся) зубов
DE50009220D1 (de) Verwendung von moxonidin zur behandlung nach herzinfarkt
Holst et al. Nature and release of products of the GRP-precursor apart from GRP